Biocon Biologics Limited (BBL), a subsidiary of Biocon Ltd. and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd. announced a strategic alliance. Under the terms of the agreement, BBL will offer approximately 15% stake to SILS, at a post-money valuation of ~$4.9 billion, for which it will…
Tag: Serum Institute of India
Novavax and Gavi Execute COVID-19 Vaccine Advance Purchase Agreement for COVAX Facility
by
•Novavax, Inc., a biotechnology company that develops next-generation vaccines for serious infectious diseases, announced that it has closed an advance purchase agreement ( APA) with Gavi, the Vaccine Alliance (Gavi) for the supply of its recombinant protein-based COVID-19 vaccine candidate to the COVAX Facility. Under the APA, Novavax is expected to produce and distribute 350…
Novavax enters COVID-19 vaccine manufacturing agreement with Serum Institute of India
by
•Novavax, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced an amendment to its existing agreement with Serum Institute of India Private Limited (SIIPL) under which SIIPL will also manufacture the antigen component of NVX‑CoV2373, Novavax’ COVID‑19 vaccine candidate. With this agreement, Novavax increases its manufacturing capacity of NVX-CoV2373 to over two…
Serum Institute owner sells Czech unit to biotechnology company Novavax for $167 mn
by
•Novavax Inc, a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced the acquisition of Praha Vaccines, a part of the Cyrus Poonawalla Group, in an all cash transaction of approximately $167 million. The acquisition includes a biologics manufacturing facility and associated assets in Bohumil, Czech Republic. The facility is expected to provide…
Codagenix and Serum Institute to co-develop a live-attenuated vaccine against COVID-19
by
•Codagenix, a clinical-stage biotechnology company developing prophylactic vaccines and oncolytic virus therapies, announced a collaboration with the Serum Institute of India to rapidly co-develop a live-attenuated vaccine against the emergent coronavirus. There are no licensed vaccines or therapeutics for this novel coronavirus, now referred to as COVID-19. A live-attenuated vaccine has multiple advantages, including mounting…